Regorafenib/Strong CYP3A4 Inhibitors
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Some medicines may change the way your liver processes regorafenib.
What might happen:
The amound of regorafenib in your blood may decrease and it may not work as well.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.FDA. Drug Approval Package: Stivarga (regorafenib) Tablets, Application:203085, Clinical Pharmacology Review. accessed at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203085Orig1s000Clin PharmR.pdf approval 09/27/2012.
2.Stivarga (regorafenib) US prescribing information. Bayer HealthCare Pharmaceuticals, Inc. May, 2013.
3.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/D rugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.